OCTA Biomarker Search in Patients with nAMD: Influence of Retinal Fluid on Time-Dependent Biomarker Response.


Journal

Current eye research
ISSN: 1460-2202
Titre abrégé: Curr Eye Res
Pays: England
ID NLM: 8104312

Informations de publication

Date de publication:
06 2023
Historique:
medline: 16 5 2023
pubmed: 10 3 2023
entrez: 9 3 2023
Statut: ppublish

Résumé

Previous studies have identified a link between optical coherence tomography (OCT)-derived and OCT angiography (OCTA)-based parameters in patients with neovascular AMD (nAMD); the latter may serve as direct biomarkers for macular neovascularization (MNV) activity. The aim of this study was to assess the individual influence of retinal thickness (RT) as well as intra- and sub-retinal fluid (IRF, SRF) presence on the treatment response over time as assessed by previously identified OCTA-derived MNV vascular parameters. During the first 3 months of anti-VEGF therapy patients were prospectively followed. RT, SRF and IRF were determined from SSOCT/A (PlexElite, Zeiss) images and using the semi-automated AngioTool software, vessel area (VA), total vessel length (TVL), total number of junctions (TNJ), junction density (JD), vessel density (VD) as well as MNV area were exported. IRF and SRF were identified manually on OCT volume scans .The associations between RT, IRF, and SRF and SSOCTA vascular parameters were analyzed using linear mixed models. 31 eyes of 31 patients with treatment-naïve and OCTA-positive nAMD MNV were included in this analysis. VA, TVL, TNJ, and MNV area show a statistically significant change over time in response to anti-VEGF treatment, even after correcting for the presence of SRF, IRF, or RT (all OCTA-based parameters VA, TVL, TNJ, and MNVarea show a strong response to anti-VEGF therapy over time, independent of the presence of IRF, SRF or RT. We conclude that the above listed OCTA parameters could contribute to our understanding of MNV biology and to guide individualized treatment in the future. The authors confirm that all ongoing and related trials are registered. ClinicalTrials.gov Number: NCT02521142.

Identifiants

pubmed: 36891909
doi: 10.1080/02713683.2023.2184318
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Vascular Endothelial Growth Factor A 0
Biomarkers 0

Banques de données

ClinicalTrials.gov
['NCT02521142']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

600-604

Auteurs

Reinhard Told (R)

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

Adrian Reumueller (A)

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

Markus Schranz (M)

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

Jonas Brugger (J)

Center for Medical Statistics, Informatics, and Intelligent Systems (CeMSIIS), Medical University of Vienna, Vienna, Austria.

Günther Weigert (G)

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

Gregor Sebastian Reiter (GS)

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

Stefan Sacu (S)

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

Ursula Schmidt-Erfurth (U)

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH